Thus, the intentionargument of our synthetic chemist is incomplete.
The Chemistry of Caramel | ScienceGeist
While the inventionand use of chemical weapons might be in the interest of a nation, and whileit might be argued from an utililarian point of view that the of weapons can sometimes be in the interest of humanity, the of new chemical weapons, like the synthesis of any substance with the intentionto harm or kill people, is definitely against the interest of humanity.
Aspirin - Molecule of the Month - School of Chemistry | …
Therefore, utilitarianism does not undermine butstrongly support the categorical moral claim that every synthesis of anew substance with the intention to harm or kill people is morally wrong.
Synthesis Of Aspirin Lab Report Free Essays
Rational drug design is a very different approach than the trial and error that led to the first use of aspirin. To design drugs that target a specific enzyme or biochemical mechanism is increasingly feasible since the 1980s, when scientific knowledge about relevant mechanisms began to accumulate. Molecular biologists had deciphered the molecular sequences of the COX enzymes and how they fold into complex three-dimensional structures. Armed with this knowledge, pharmacologists set about finding small drug molecules that interfere with only COX2 and not COX1.
# Question of the day | Biochemistry for Medics – …
Both Celebrex and Vioxx made the 2001 list of top ten drugs by global sales, beating the famous impotence drug Viagra, introduced in 1998. Clinical superiority is not the only reason for the high dollar sales of COX2 inhibitors. Another reason is that super aspirins are much more expensive than aspirin. Social critics grumble that the new drugs are not worth their high prices, but people whose drug bills are covered by health insurance do not care. They demand the best, whether or not aspirin upsets their stomachs; they pay the same insurance premium anyway. COX2 inhibitors grossed $5.7 billions and accounted for 23 percent of the pain and inflammation drug market in 2001. That was smaller than the 30 percent for the old COX inhibitors, but the trend of replacement was unmistakable. Optimistic analysts projected that by 2010, the market share of COX2 inhibitors would more than double that of COX inhibitors.